despite neutral imaging results, adalimumab did improve other key markers of inflammation in the blood including glyca, crp, tnf, and il-6..
.previous efforts to treat babies with the same protein shortly after birth had failed, schneider said...: "targeted cgrp small molecule antagonists for acute migraine therapy.".